<DOC>
	<DOCNO>NCT01596920</DOCNO>
	<brief_summary>The primary objective present study establish randomize controlled trial , safety efficacy weekly Grafix® administration versus control patient chronic diabetic foot ulcer . The primary endpoint complete wound closure index wound , define 100 % re-epithelialization determine Investigator . Grafix® product regulate use US FDA Human Cellular Tissue Based Product ( HCT/P ) Title 21 CFR Part 1271 .</brief_summary>
	<brief_title>Grafix® DFU : Open-Label Extension Option Evaluate Safety &amp; Efficacy Grafix® Chronic Diabetic Foot Ulcers</brief_title>
	<detailed_description>The treatment indication chronic , diabetic foot ulcer ( DFUs ) 1cm2 15cm2 locate malleoli plantar dorsal surface foot . Patients must confirm Type I Type II Diabetes . Patients receive treatment every week 12 week duration Single-Blind Treatment phase trial . Patients receive Grafix® control evaluate primary efficacy 84 day , safety wind re-occurrence 84 day wound closure . Patients control group whose wound close end treatment may offer Grafix® Open-Label Treatment phase . The Open-Label Treatment phase last additional 84 day .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>1 . Between 18 year 80 year age inclusive , date screen 2 . Confirmed diagnosis Type I Type II Diabetes 3 . An Index Ulcer define chronic ( presence wound &gt; 4 week ) present 52 week Screening Visit 4 . Index Ulcer locate malleoli plantar dorsal surface foot 5 . The Index Ulcer 1cm2 15 cm2 Screening Visit 6 . The Index Ulcer extend dermis subcutaneous tissue without evidence expose muscle , tendon , bone , joint capsule 7 . Wound free necrotic debris 8 . Patient adequate circulation foot document either : Ankle Brachial Index ( ABI ) &gt; 0.70 &lt; 1.30 , In patient noncompressible ankle vessel define ABI ≥ 1.30 , Toe Brachial Index ( TBI ) ≥ 0.50 In patient noncompressible ankle vessel define ABI ≥ 1.30 TBI perform ( e.g. , toe absent , wound present , site perform TBI ) , Doppler waveform posterior tibial dorsalis pedis artery ankle consistent adequate flow foot ( biphasic triphasic ) diagnostic confirmation adequate flow ( e.g. , duplex imaging , normal pulse volume record [ PVR ] test ) . 1 . Index Ulcer nondiabetic pathophysiology 2 . Gangrene present part affect foot 3 . Index Ulcer active Charcot deformity 4 . The long dimension Index Ulcer exceed 5 cm Baseline Visit 5 . Patient currently receive dialysis 6 . Patient glycated hemoglobin A1c ( HbA1c ) level &gt; 12 % 7 . Chronic oral steroid use &gt; 7.5 mg daily 8 . Requiring intravenous ( IV ) antibiotic treat index wound infection 9 . Patient ulcer within 15cm Index Ulcer identify study consideration 10 . Patient receive oral parenteral corticosteroid , immunosuppressive cytotoxic agent 11 . Patient Human Immunodeficiency Virus ( HIV ) positive Acquired Immune Deficiency Syndrome ( AIDS ) 12 . Current evidence osteomyelitis , cellulitis , evidence infection include fever pu drainage wind site 13 . Patient active malignancy nonmelanoma skin cancer 14 . Patient 's Index Ulcer decrease ≥ 30 % 1week screening period determine criterion provide Wound Core Lab 15 . Patient 's random blood sugar &gt; 450 mg/dl screen 16 . Patient untreated alcohol substance abuse time screen 17 . Pregnant woman 18 . Patient currently enrol participate another investigational device , drug , biological trial within 60 day screen 19 . Patient allergy primary secondary dressing material use trial 20 . Patient within last 30 day , currently undergo , plan wound treatment enzymes , growth factor , live skin , dermal substitute advance biological therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Chronic DFUs</keyword>
	<keyword>Diabetic Foot Ulcers</keyword>
</DOC>